Findings of the 3-Month Supportive Treatment with Oncoxin Solution Beside the Standard Modalities of Patients with Different Neoplastic Diseases.

Abstract

The incidence of Cancer is still increasing worldwide, specially, at an alarming rate in the developing countries and remain one of the major cause of morality worldwide. The role of different antioxidants, both in fruits and vegetable and in synthetic form as chemo-preventive measure is now well established from different studies. The incidence of cancer is lower in those countries where the traditional diet provides plenty of antioxidants. The aim of this study is to evaluate standard modalities of patients with different neoplastic diseases. Three identically designed, open and multi-centric studies were conducted at the same time in Bangladesh in 2008-2009. Efficacy of antioxidant rich product, Oncoxin, in head and throat, breast and uterine cervix cancer, when administered with conventional oncologic therapy Each study included 30 patient couples with similar stages of cancer. One patient of each couple received the standard treatment for their stage (reference group). The other (experimental group) also received Oncoxin for 365 days. The result gathered in the 3 studies showed that the administration of Oncoxin led to a significant improvement of the quality of life of patients, fewer episodes of depression and increased optimism. These patients handled better the radiotherapy and chemotherapy sessions with fewer and less intense adverse reactions. During the final visit, it was observed a 59.26% increase in the Karnofsky index in the experimental group compared to 30.38% in the reference group, and a 16.05% drop (76.93% due to deaths) in the experimental group for 39.24% (64.52% due to deaths) in the reference group. Survival rates were greater in the experimental group in all three studies (87.65% versus 74.68%). The treatment with ONCOXIN Solution proves its effectiveness as a treatment modality associated with complex oncological treatment, the short and medium terms.TAJ 2009; 22(1): 172-175

Ocoxin as a complement to first line treatments in cancer

“…Interestingly, 26% of Ocoxin supplemented patients lived for another 3 months, while 21% of Ocoxin having individuals prolonged their life for 9 months 61 . This observation goes in line with that reported by Uddin et al (2018) , observing increased survival rates in Ocoxin receiving patients from head and neck, breast and uterine cervix cancer compared to control group (87,65% vs 74,68%, respectively) 31 , always under CT routine. In line with these findings, clinical trials using Melatonin as adjuvant to CT resulted in 1 year increased survival rate while promoting the regression of tumors 62 .…”

“…Petients with higher Karnofsky index show better prognosis. It is to note that Ocoxin administration along with CT resulted in 59,26% increase in Karnofsky index compared to 30,38 reported in patients receiving CT alone, suffering from different neoplasic diseases, such as head and neck, breast and uterine cervix cancer [31]. In concordance, other natural compounds have shown efficacy when using as adjuvant along with CT regimens, increasing the Karnofsky index in cancer patients, such as those suffering from Non Small Cell Lung Cancer (NSCLC) [44].…”

“…Ocoxin has shown a positive effect in mitigating CT-related toxicity, allowing patients to tolerate better the RT. In fact, Ocoxin reduced the number and the intensity of adverse episodes in head and neck, breast and uterine cervix cancer patients 31 . These results were recently confirmed by Chon-rivas et al (2018) in head and neck cancer 45 .…”

“…Interestingly, increased degrees of oxidative stress, which is one of the catalyzators of the antitumor effect of CT, are associated with depression and anxiety symptoms [30]. It is to note that Ocoxin when administered to cancer patients improved their quality of life [31,32], which was accompanied by an increased optimism, therefore, reducing the number of episodes of depression [31]. Moreover, Kaidarova et al (2019) described improved quality of life along with increased well-being in patients receiving Ocoxin supplementation, compared to that of patients without Ocoxin [33].…”

Oncoxin‑Viusid^® may improve quality of life and survival in patients with hormone‑refractory prostate cancer undergoing onco‑specific treatments

“…In a Japanese clinical study carried out in terminal stage patients of hepatocellular carcinoma, it was observed that 21% of patients were alive at the end of the treatment in the treatment group, whereas in the control group they were dead (79). Another clinical study in Bangladesh demonstrated more tolerance to cancer treatment, which was found to improve patient survival and quality of life (80). A clinical study of pancreatic cancer proved that OV reduced the stromal-mediated chemoresistance (81).…”